PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 1, 1984Clinical Infectious Diseases33 citations

Experiences Associated with the Use of Live Poliovirus Vaccine in Hungary, 1959–1982

View Full Paper
IDI Dömök

Key Result

Nationwide vaccination with live Sabin poliomyelitis vaccine in Hungary reduced the mean annual incidence of poliomyelitis from 12 to 0.03 per 100,000 population between 1961 and 1982.

Study Design

Type

Observational

Multicenter

Yes

Structured PICO

Does the live Sabin poliomyelitis vaccine reduce poliomyelitis incidence and what is the risk of vaccine-associated poliomyelitis in children?

P
Population
Nationwide population of children in Hungary vaccinated with live Sabin poliomyelitis vaccine between 1959 and 1982.
E
Exposure
Live Sabin poliomyelitis vaccine (monovalent vaccines administered in the sequence type 1, 3, and 2 in annually repeated nationwide campaigns)
C
Comparator
Pre-vaccination period (previous five years)
O
Outcome
Incidence of poliomyelitis and vaccine-associated poliomyelitissafety

The live Sabin poliomyelitis vaccine drastically reduced polio incidence in Hungary, with an acceptable risk of vaccine-associated poliomyelitis given the benefits.

Main Result

Absolute Event Rate: 0.03% vs 12%

Abstract

Live Sabin poliomyelitis vaccine has been given in Hungary since December 1959. Generally, monovalent vaccines--administered in the sequence type 1, 3, and 2--have been used in annually repeated nationwide campaigns. Each type was administered within a week all over the country, with an interval of five to eight weeks between administrations. In the initial campaigns, children younger than 14 years of age were vaccinated. Since 1962, children between two and 38 months of age have been vaccinated annually. As a result of the vaccination program, the mean annual incidence of poliomyelitis declined to 0.03 per 100,000 population between 1961 and 1982 from a level of 12 per 100,000 observed over the previous five years. Epidemiologic and virologic evidence indicated that 47 (82%) of 57 cases registered since 1961 were vaccine-associated. Circumstances connected with the special vaccination practice in Hungary gave an opportunity to estimate the risk of vaccine-associated poliomyelitis. For recipients receiving the vaccine for the first time, the estimated risks for each type of vaccine were type 1, 0.99; type 2, 0.65; and type 3, 8.91 per million and for susceptible contacts, type 1, 0; type 2, 3.62; and type 3, 4.97 per million. The author's opinion is that these rates of risk are acceptable in view of the benefits provided by the live vaccine, especially under circumstances when importation of wild polioviruses that circulate widely in extended regions of the world may commonly occur.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

I Dömök (1984) conducted an observational in Poliomyelitis. Live Sabin poliomyelitis vaccine vs. Historical incidence (previous five years) was evaluated on Mean annual incidence of poliomyelitis per 100,000 population. Nationwide vaccination with live Sabin poliomyelitis vaccine in Hungary reduced the mean annual incidence of poliomyelitis from 12 to 0.03 per 100,000 population between 1961 and 1982.

synapsesocial.com/papers/6a6c2221109fb9aed0245778https://doi.org/10.1093/clinids/6.supplement_2.s413
Ask AI
Helpful
Bookmark
Share
View Full Paper